Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice

@article{Gavioli2004AntidepressantlikeEO,
  title={Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice},
  author={Elaine C. Gavioli and Christopher W Vaughan and Giuliano Marzola and Remo Guerrini and Vanessa A. Mitchell and Silvia Zucchini and Thereza C.M. de Lima and Giles Alexander Rae and Severo Salvadori and Domenico Regoli and Girolamo Calo},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2004},
  volume={369},
  pages={547-553}
}
Receptor antagonist and knockout studies have demonstrated that blockade of signalling via nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) has antidepressant-like effects in mice submitted to the forced swimming test (FST). The aim of the present study was to explore further the antidepressant-like properties of the NOP antagonist UFP-101 in different species (mouse and rat) and using different assays [FST and tail suspension test (TST)], and to investigate the mechanism(s) involved in… 
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands
  • E. Gavioli, G. Calo
  • Psychology, Medicine
    Naunyn-Schmiedeberg's Archives of Pharmacology
  • 2006
TLDR
A rather unique behavioral profile since the activation or the blockade of a given neuropeptide receptor produces, in most of the cases, both antidepressant- and anxiolytic-like effects.
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands
TLDR
The results suggest that the action of a NOP ligand on emotional states is better predicted based on its β-arrestin 2 rather than G-protein efficacy.
Anxiolytic-like effect of central administration of NOP receptor antagonist UFP-101 in rats submitted to the elevated T-maze
TLDR
The results showed that the central administration of UFP-101 presents an anxiolytic-like effect in rats evaluated in the ETM test, providing new insights for drug development to treat anxiety disorders targeting the N/OFQ-NOP receptor system.
Chronic treatment with the selective NOP receptor antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats
TLDR
It is demonstrated that chronic treatment with UFP-101 produces antidepressant-like effects in rats subjected to CMS supporting the proposal that NOP receptors represent a candidate target for the development of innovative antidepressant drugs.
Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
TLDR
Clinical findings showed that plasma N/OFQ levels were significantly altered in major and post-partum depression, and bipolar disease patients, and chronic administration of a NOP antagonist restored these alterations.
Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies
TLDR
Results clearly indicate that endogenous N/OFQ-NOP receptor signalling plays an important role in controlling anxiety- and mood-related behaviours, exercise-driven locomotor activity and nociception.
Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test
TLDR
The results indicate that the antidepressant-like effect of adenosine in the FST appears to be mediated, at least in part, by an interaction with 5-HT1A receptors.
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences
TLDR
The overall effect of blocking NOP receptor signalling, by either systemic pharmacological antagonism or genetic ablation, indicates that the spinal antinociceptive action prevails over supraspinal pronocICEptive effects.
Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress
TLDR
The view that blockade of NOP receptors produces antidepressant-like effects in CMS associated with positive effects on neurogenesis and FGF-2 expression is supported, therefore, NOP receptor receptors may represent a target for innovative antidepressant drugs.
Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness
TLDR
Findings support the proposal that NOP receptor antagonists are worthy of development as innovative antidepressant drugs and reversed helplessness similarly to the classical antidepressants.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Blockade of nociceptin/orphanin FQ–NOP receptor signalling produces antidepressant‐like effects: pharmacological and genetic evidences from the mouse forced swimming test
TLDR
Results indicate that blockade of the N/OFQ‐NOP receptor signalling in the brain produces antidepressant‐like effects in the mouse FST, and support the NOP receptor as a candidate target for the development of innovative antidepressant drugs.
Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test
TLDR
It is suggested that nociceptin, and its receptor, may play a role in depressive disorders and that the nocICEptin system could represent a novel target for the development of new antidepressant drugs.
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice
TLDR
It is demonstrated that NC inhibits LA in mice by activating OP4 receptor sites using NC receptor (OP4) agonist and a pure antagonist of OP4 sites, respectively.
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5‐hydroxytryptamine release in the mouse neocortex
TLDR
It is concluded that Nop receptors in the mouse are subtly different from the homologous receptor population in the rat, strengthening the view that there exist species differences in the pharmacology of central NOP receptors.
UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPγ35S binding studies
TLDR
It is suggested that due to its high potency UFP-101 should prove a further useful tool in the evaluation of the N/OFQ-NOP receptor system.
Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs
TLDR
It is shown that intravenous N/OFQ, via NOP receptors, elicits hypotension and bradycardia also in the anaesthetized guinea pig and that the decrease in MAP and HR are positively correlated with the decreases in the plasma noradrenaline level.
Pharmacology of nociceptin and its receptor: a novel therapeutic target
TLDR
New advances have contributed to better understanding of the pathophysiological role of the NC/OP4 system, and ultimately will help to identify the therapeutic potential of new OP4 receptor ligands.
[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
TLDR
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.
The isolation of an opioid receptor-related clone soon led to the isolation and characterization of a new neuropeptide, termed orphanin FQ or nociceptin (OFQ/N). This heptadecapeptide binds to the
Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity
TLDR
The results of the present study indicated that, at low doses, venlafaxine inhibited serotonin reuptake, while at higher doses it inhibited both serotonin and noradrenaline reuptakes.
...
1
2
3
4
...